Neuraxis

Neuraxis Net Tangible Assets

The Net Tangible Assets of Neuraxis (NRXS) as of Nov 16, 2026 is 3.40 M USD. In the previous year, Net Tangible Assets was 1.97 M USD — a change of 72.46% (higher).

Net Tangible Assets

3.40 MUSD

YoY

72.46%

Last updated:

Net Tangible Assets of Neuraxis is 2025 3.40 M USD. Net Tangible Assets of Neuraxis was 2024 1.97 M USD. It decreases by 72.46% higher compared to the previous year.

The Neuraxis Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2020
1.61 M USD
Jan 1, 2021
-845,660.00 USD
Jan 1, 2022
-5.65 M USD
Jan 1, 2023
-1.51 M USD
Jan 1, 2024
1.97 M USD
Jan 1, 2025
3.40 M USD
The Neuraxis Net Tangible Assets history
YEARNet Tangible AssetsYoY
3.40 MUSD+72.46%
1.97 MUSD-230.42%
-1.51 MUSD-73.27%
-5.65 MUSD+568.54%
-845,660.00USD-152.40%
1.61 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuraxis stock

Net Tangible Assets of Neuraxis is 3.40 M USD in 2025.

Net Tangible Assets of Neuraxis changed from 1.97 M USD to 3.40 M USD, representing a 72.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Neuraxis since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuraxis

All Key Metrics — Neuraxis